Our primary objective is to develop safe, efficient and scalable methods to engineer lymphocytes for immunotherapy. We provide a novel technology for the engineering of B cells as well as T cells, in vivo as well as ex vivo.

 

T-cell engineering for cancer immunotherapy has shown clinical success, but it cannot be applied to most patients because it relies on cumbersome ex vivo manipulations that are performed in specialized centers only.

​

Our lab develops novel immunotherapy approaches, targeting immune genes into the genome of white blood cells. In particular, we target chimeric antigen receptor (CAR) or T cell receptor (TCR) genes into the genome of T cells, and we target antibody genes into the genome of B cells.